Alkem launches semaglutide pre-filled syringes in India at INR350

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹5318.00

prior close

₹5230.50

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.7% vs market

Pharmaceuticals peers, median of 164sector-0.3%-1.2% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Midcap 150 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.5

15m

+0.1

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.2-1.7-0.3-1.2

Next day

-0.8-0.2-0.6-0.3-0.5

-0.6+0.2-0.8-0.3-0.3

-1.3-0.1-1.2+0.3-1.5

+1.0-1.5+2.5-0.7+1.7

+0.1-0.2+0.3+0.5-0.4

-0.2-2.4+2.1-0.5+0.3

15d

+1.5+2.6-1.1+4.7-3.1

+3.4+3.0+0.4+6.0-2.5

+7.3+5.2+2.1+6.3+1.0

-1.8+3.8-5.6+7.6-9.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories has become the first company in India to launch semaglutide in single-shot pre-filled syringes, priced from INR350. The company received DCGI approval to manufacture and market the product for Type 2 diabetes and obesity. This adds to the pen format launched in March 2026, with vials coming soon. The move aims to widen patient access and lower entry barriers. Alkem is India's sixth-largest pharma firm.

Likely market impact

First-mover in India's growing GLP-1 market; affordable pricing and multiple formats may boost share in diabetes and obesity segments.